search
Back to results

Methylphenidate for Treating Children With ADHD and Tourette Syndrome

Primary Purpose

Attention Deficit Disorder With Hyperactivity, Tourette Syndrome

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Methylphenidate
Sponsored by
Stony Brook University
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Attention Deficit Disorder With Hyperactivity focused on measuring ADHD

Eligibility Criteria

6 Years - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of ADHD or ADHD plus Tourette syndrome

Exclusion Criteria:

  • Determined to be dangerous to self or others
  • Scores less than 70 on an IQ test
  • Any seizure disorder, major organic brain dysfunction, major medical illness, major mood disorder, psychosis, pervasive developmental disorder, or peripheral sensory loss
  • Any condition that may make use of methylphenidate unsafe

Sites / Locations

    Outcomes

    Primary Outcome Measures

    ADHD symptoms
    Oppositional and aggressive behavior
    Frequency and severity of tics and obsessive compulsive disorder symptoms
    Tic impairment, tic severity, and clinical response
    Anxiety and mood symptoms
    Rebound tic exacerbation
    Adverse drug reactions (all measured at 2-week intervals throughout the study)

    Secondary Outcome Measures

    Full Information

    First Posted
    February 28, 2007
    Last Updated
    October 29, 2013
    Sponsor
    Stony Brook University
    Collaborators
    National Institute of Mental Health (NIMH)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00441649
    Brief Title
    Methylphenidate for Treating Children With ADHD and Tourette Syndrome
    Official Title
    Methylphenidate Treatment of ADHD in Children With Tourette Syndrome
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2013
    Overall Recruitment Status
    Completed
    Study Start Date
    February 2000 (undefined)
    Primary Completion Date
    June 2004 (Actual)
    Study Completion Date
    January 2007 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Stony Brook University
    Collaborators
    National Institute of Mental Health (NIMH)

    4. Oversight

    5. Study Description

    Brief Summary
    This study will evaluate the safety and effectiveness of methylphenidate in treating attention deficit hyperactivity disorder in children with both attention deficit hyperactivity disorder and Tourette syndrome.
    Detailed Description
    Tourette syndrome is a neurological disorder that is characterized by repetitive, involuntary movements and vocalizations called tics. Many children with Tourette syndrome also have attention deficit hyperactivity disorder (ADHD), which is one of the most common childhood mental disorders. Symptoms of ADHD usually include impulsiveness, inattention, and hyperactivity. ADHD is commonly treated with a stimulant medication, such as methylphenidate. It is under debate, however, whether using stimulants in children with Tourette syndrome exacerbates tics associated with the disorder. This study will evaluate the safety and effectiveness of methylphenidate in treating ADHD in children who have both ADHD and Tourette syndrome. Participants in this 6-week, double blind study will receive three doses of methylphenidate over the course of the study. Each dose will be taken twice daily, approximately 3.5 hours apart, for 2 weeks. Medication will be dispensed at study visits, which will occur once every 2 weeks. At each study visit, participants will take a dose of the medication. About an hour after ingesting the medication, they will be observed in a classroom setting by study physicians. Participants will then complete a Continuous Performance Test, which will measure their voluntary attention levels. The following will be assessed at study visits: ADHD symptoms; oppositional and aggressive behavior; frequency and severity of tics and obsessive compulsive disorder symptoms; rebound tic exacerbation; effects of methylphenidate on tic-related problems with self-esteem, family life, academic and social performance, and overall tic severity; anxiety and mood symptoms; and adverse drug reactions. Parents and teachers will also complete assessments of participants' behavior on 2 days of each week for the duration of the study.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Attention Deficit Disorder With Hyperactivity, Tourette Syndrome
    Keywords
    ADHD

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    Double
    Allocation
    Non-Randomized
    Enrollment
    71 (false)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Methylphenidate
    Primary Outcome Measure Information:
    Title
    ADHD symptoms
    Title
    Oppositional and aggressive behavior
    Title
    Frequency and severity of tics and obsessive compulsive disorder symptoms
    Title
    Tic impairment, tic severity, and clinical response
    Title
    Anxiety and mood symptoms
    Title
    Rebound tic exacerbation
    Title
    Adverse drug reactions (all measured at 2-week intervals throughout the study)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    6 Years
    Maximum Age & Unit of Time
    12 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Diagnosis of ADHD or ADHD plus Tourette syndrome Exclusion Criteria: Determined to be dangerous to self or others Scores less than 70 on an IQ test Any seizure disorder, major organic brain dysfunction, major medical illness, major mood disorder, psychosis, pervasive developmental disorder, or peripheral sensory loss Any condition that may make use of methylphenidate unsafe
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Kenneth D. Gadow, PhD
    Organizational Affiliation
    State University of New York at Stony Brook
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    7771914
    Citation
    Gadow KD, Sverd J, Sprafkin J, Nolan EE, Ezor SN. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry. 1995 Jun;52(6):444-55. doi: 10.1001/archpsyc.1995.03950180030005. Erratum In: Arch Gen Psychiatry 1995 Oct;52(10):836.
    Results Reference
    background
    PubMed Identifier
    10197827
    Citation
    Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999 Apr;56(4):330-6. doi: 10.1001/archpsyc.56.4.330.
    Results Reference
    background

    Learn more about this trial

    Methylphenidate for Treating Children With ADHD and Tourette Syndrome

    We'll reach out to this number within 24 hrs